AbbVie (ABBV) Stock Gets Fair Value Bump After Analyst Target Increases — Oct 24, 2026

AbbVie's analyst narrative has shifted again, with fair value in one model now set at US$284.79 compared with US$278.61 previously, and other price targets clustering in a wide US$260 to US$325 range. Recent commentary links these higher targets to confidence in AbbVie's portfolio across i...

U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease — Oct 23, 2026

Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector (OBI) device throughout the course of treatment In the pivotal Phase 3 AFFIRM study, subcutaneous (SC) SKYRIZI® achieved superior clinical remi...

BMY vs. ABBV: Which Pharma/Biotech Stock Offers More Upside Potential? — Oct 23, 2026

Bristol Myers Squibb BMY and AbbVie ABBV are two leading pharma/biotech players with diversified portfolios and a strong global presence. BMY has built a robust portfolio comprising drugs for oncology, hematology, immunology, cardiovascular, neuroscience and other therapeutic areas. AbbVie...

Global Dental Soft Tissue Wound Care Market Size, Share, and Forecast by Product, 2026-2032 | Plug, Tape, and Foam Demand to Drive 11.8% CAGR and a $390 Million Market — Oct 23, 2026

Company Logo The global dental soft tissue wound care market is projected to grow from nearly $180 million in 2025 to nearly $390 million by 2032, a new Research and Markets report finds, with ZimVie leading ahead of AbbVie and Henry Schein, though cost sensitivity and limited reimbursemen...

AbbVie (ABBV) Earnings Expected to Grow: What to Know Ahead of Next Week's Release — Oct 23, 2026

The market expects AbbVie (ABBV) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might ...

Avalo Therapeutics Abdakibart Potential Intact After AbbVie Data, Wedbush Says — Oct 22, 2026

Avalo Therapeutics' (AVTX) abdakibart remains promising for hidradenitis suppurativa, with phase 2…...

Jim Cramer and Ken Fisher Like This Healthcare Stock — Oct 22, 2026

With AI stocks making waves, some prudent investors are looking at healthcare names to diversify amid concerns about an AI data center slowdown. AbbVie Inc. (NYSE:ABBV) ranks eighth on our list of the top 10 stocks Jim Cramer and billionaire Ken Fisher like. The stock has gained about 23% ...

AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa — Oct 22, 2026

In the Phase 3 INTREPID study, lutikizumab achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16 compared with placebo1 Lutikizumab met 8 ranked secondary endpoints, including significant improvements in HS-related skin pain at Week 8 and signi...

AbbVie (ABBV) Is Considered a Good Investment by Brokers: Is That True? — Oct 22, 2026

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? Before we d...

AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors — Oct 21, 2026

AbbVie (ABBV) closed at $284.80 in the latest trading session, marking a -1.48% move from the prior day. This move lagged the S&P 500's daily gain of 0.58%. At the same time, the Dow added 0.69%, and the tech-heavy Nasdaq gained 1.05%. Coming into today, shares of the drugmaker had gained ...